Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2013 by University of Pittsburgh
Sponsor:
Information provided by (Responsible Party):
Olivera Finn, University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT01720836
First received: October 31, 2012
Last updated: December 2, 2013
Last verified: December 2013
  Purpose

All subjects will receive the vaccine subcutaneously every 3 weeks x 3 and then every 3 months for 3 years. The rationale for using Poly-ICLC as an adjuvant are two ongoing trials at University of Pittsburgh Cancer Institute (UPCI) of the MUC1 100mer peptide vaccine - one as a therapeutic vaccine in subjects with metastatic castrate resistant prostate cancer and the other in subjects with advanced colonic adenomas at risk for developing colon cancer. The same formulation, MUC1 100mer peptide admixed with Poly-ICLC, is used in both trials. There has been no toxicity observed and the vaccine is highly immunogenic in early disease. In the proposed NSCLC trial the anti-MUC1 immune response will be thoroughly characterized.


Condition Intervention Phase
Non-small Cell Lung Cancer (NSCLC)
Biological: Vaccine + PolyICLC
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Study of the Immunogenicity of the MUC1 Peptide - Poly-ICLC (Polyinosinic-polycytidylic Acid Stabilized With Polylysine and Carboxymethylcellulose) OR HILTONOL™ Adjuvant Vaccine in Patients With Localized and Locally Advanced Non-Small Cell Lung Cancer

Resource links provided by NLM:


Further study details as provided by University of Pittsburgh:

Primary Outcome Measures:
  • Immunologic response [ Time Frame: 3 years ] [ Designated as safety issue: No ]
    Immunologic response will be measured by increases in anti MUC1 antibody titers post vaccination at different stages of disease: localized (Stage I, II) or locally advanced (Stage III) non-small cell lung cancer.


Secondary Outcome Measures:
  • anti-MUC1 immunity [ Time Frame: 3 years ] [ Designated as safety issue: No ]
    To assess spontaneous anti- MUC1 immunity in response to cancer prior to administration of the MUC1 vaccine

  • Association between baseline MUC1 immunity and vaccine [ Time Frame: 3 years ] [ Designated as safety issue: No ]
    To assess the association between baseline MUC1 immunity and vaccine - induced increases in anti MUC1 antibodies

  • Immunocompetence versus immunosuppression [ Time Frame: 3 years ] [ Designated as safety issue: No ]
    To characterize the change in the balance between immunocompetence (response of T cells to polyclonal stimulation) versus immunosuppression at different stages of disease {check for increased numbers of regulatory T cells (Treg) and Myeloid-Derived Suppressor Cells (MDSC)}

  • MUC1 associated safety [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
    To monitor adverse events associated with the study agents

  • anti-MUC1 response association with recurrence or progression [ Time Frame: 3 years ] [ Designated as safety issue: No ]
    To evaluate the association between the anti-MUC1 response (preexistent and/or induced or boosted by the vaccine) and recurrence or progression of lung cancer


Estimated Enrollment: 30
Study Start Date: November 2012
Estimated Study Completion Date: November 2017
Estimated Primary Completion Date: November 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Stage IA or I/II NSCLC
Resection or radiotherapy without adjuvant chemotherapy followed by 3 cycles of vaccination.
Biological: Vaccine + PolyICLC
The vaccine will consist of 100 micrograms of MUC1 100mer peptide dissolved in 50 micro-liters of sterile saline, admixed with 500 micrograms of Hiltonol® in 250 microliters volume, for a total injection volume of 300 microliters.
Experimental: Stage IB/II/IIIA
Resection and adjuvant chemotherapy followed by 3 cycles of vaccination.
Biological: Vaccine + PolyICLC
The vaccine will consist of 100 micrograms of MUC1 100mer peptide dissolved in 50 micro-liters of sterile saline, admixed with 500 micrograms of Hiltonol® in 250 microliters volume, for a total injection volume of 300 microliters.
Experimental: Stage IIIA or IIIB
Concomitant chemo-irradiation followed by 3 cycles of vaccination.
Biological: Vaccine + PolyICLC
The vaccine will consist of 100 micrograms of MUC1 100mer peptide dissolved in 50 micro-liters of sterile saline, admixed with 500 micrograms of Hiltonol® in 250 microliters volume, for a total injection volume of 300 microliters.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC)
  • All subjects must have one of the following stages: Stage IA(T1NO); IB (T2NO), II & IIIA (N2 negative); IIIA (N2+), IIIB (N3+)
  • Patients must have stable disease at the time of enrollment
  • Women and men at least 18 years of age
  • ECOG performance status 0-1(Appendix A)
  • Subjects must be within 4 to 6 weeks of standard of care treatment for their particular stage of disease
  • Subjects must have acceptable organ and marrow function as defined below:

    • Leukocytes > 3,000/µL
    • Absolute Neutrophils > 1,500/µL
    • Hemoglobin > 10 g/dL
    • Platelets > 100,000/µL
    • Total Bilirubin within normal institutional limits
    • Creatinine within normal institutional limits OR
    • Creatinine clearance > 60 mL/min/1.73 m2 for subjects with above normal AST and ALT with alkaline phosphatase within < 1.5 times upper limit of normal
  • The effects of a MUC1vaccine on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, men and women of childbearing potential must be willing to use effective contraception (hormonal barrier method of birth control; abstinence) while on study treatment and for at least 3 months thereafter. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately

Exclusion Criteria:

  • Subjects may not be receiving any other investigational agents
  • Positive ANA lab result
  • Known Hepatitis B on immunomodulators (i.e. interferon)
  • Known Hepatitis C on immunomodulators (i.e. interferon)
  • No prior vaccine therapy
  • Patients may not be receiving any steroids or other anti-immune therapy at the time of registration.
  • Subjects must not be more than 6 weeks from standard of care treatment for their particular stage of disease
  • Subjects must not have post-obstructive pneumonia or other serious infection at the time of registration or other serious underlying medical condition that would impair the ability of the subjects to receive protocol treatment
  • Prior resection of lung cancer is allowed, if at least five years have elapsed between previous resection and registration
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant women are excluded from this study. Women of childbearing potential must have a negative pregnancy test
  • Subjects with immune deficiency are not expected to respond to the vaccine. Therefore, known HIV-positive patients are excluded from the study
  • Subjects with a history of known autoimmune disease are excluded from this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01720836

Contacts
Contact: Julie Ward, RN, BSN 412-647-8583 wardj@upmc.edu
Contact: Judy Forster, RN, BSN, BS 412-647-8579 forsterje@upmc.edu

Locations
United States, Pennsylvania
UPMC Hillman Cancer Center Recruiting
Pittsburgh, Pennsylvania, United States, 15232
Sponsors and Collaborators
Olivera Finn
Investigators
Principal Investigator: David Odell, MD University of Pittsburgh
  More Information

No publications provided

Responsible Party: Olivera Finn, Professor of Immunology, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT01720836     History of Changes
Other Study ID Numbers: 11-094, 902168
Study First Received: October 31, 2012
Last Updated: December 2, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Poly I-C
Poly ICLC
Anti-Infective Agents
Antiviral Agents
Immunologic Factors
Interferon Inducers
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014